Business Context and Reporting Period
This Form 8-K was filed by Health Catalyst, Inc. on June 23, 2021. The report details a strategic acquisition agreement entered into on the same date to acquire Twistle, Inc., a Delaware corporation.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels for the reporting period. The primary financial data relates to the acquisition terms:
- Aggregate Purchase Price: Approximately $104.5 million.
- Potential Earn-out: Up to $65 million contingent on performance targets.
- Equity Consideration: 830,704 shares of Health Catalyst Common Stock.
- Valuation Basis: Shares valued at a closing reference price of $56.60 (10-day average trading price ended June 21, 2021).
- Expected Closing: Early in the third quarter of 2021.
Material Changes
The material change reported is the execution of the acquisition agreement for Twistle, Inc. This transaction represents a significant expansion of Health Catalyst's portfolio and involves the issuance of unregistered equity securities under Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D.
Guidance, Outlook, and Risks
Management expects the transaction to close early in Q3 2021, subject to customary closing conditions. The earn-out provision extends through June 30, 2022, with share issuance dependent on meeting specific performance targets. The filing includes a cautionary note regarding forward-looking statements, highlighting risks such as:
- Adverse and unpredictable macro-economic conditions.
- Risks related to the successful closing of the transaction.
- Challenges associated with the integration of the two companies.
Investor Verification Checklist
- Verify the final closing date of the Twistle acquisition against the expected Q3 2021 timeline.
- Monitor the performance targets for the earn-out period ending June 30, 2022, to determine the final equity issuance.
- Review the attached press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) for strategic rationale details.
- Confirm the impact of the $104.5 million purchase price on the company's balance sheet upon closing.